“We are on track to meet FY19 guidance of Underlying EBIT of $75 million, with the 2H19 set to benefit from cost savings already achieved in the business.”
“Sales Revenue for the six months was down 2.0% to $1.96 billion, largely impacted by the decline in low margin Hepatitis C medications and some impact from the up-scheduling of codeine-based products from February. Excluding Hepatitis C alone, sales revenue was up 3.2% to $1.82 billion.”
The Hep C meds impact and up-schedule of codeine is affecting all wholesalers, including EBOS.
However, excluding Hep C, good to see sales revenue up 3.2%.
Ann: Sigma 2018/19 Half Year Results Presentation, page-2
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.89 |
Change
0.110(3.96%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.82 | $2.92 | $2.76 | $22.11M | 7.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 509791 | $2.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.90 | 226186 | 6 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
